Intellia had already paused dosing in trials of nex-z in transthyretin amyloidosis after the patient was hospitalized due to a serious adverse event.

The firm recorded $58 million in sales for the autologous TIL therapy, which it is working on moving into earlier melanoma settings and other tumor types.

The UK regulator is creating a new framework for how it will approve rare disease treatments, which it intends to publish in ...

AstraZeneca's net profit in Q3 2025 was $2.54 billion, or $1.64 per share, compared to $1.43 billion, or $.92 per share, in Q3 2024. The firm beat the Wall Street consensus EPS estimate of $1.13.